Argireline.
Argireline is the trade name for acetyl hexapeptide-3 (also designated acetyl hexapeptide-8 under INCI naming), a synthetic six-amino-acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) developed in the early 2000s as a topical cosmetic ingredient.
Argireline is the trade name for acetyl hexapeptide-3 (also designated acetyl hexapeptide-8 under INCI naming), a synthetic six-amino-acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) developed in the early 2000s as a topical cosmetic ingredient. Argireline is cosmetic / topical, and PepCue grades its published evidence D tier (39/100). Also known as acetyl hexapeptide-8. This is a research reference, not medical or dosing advice.
What it is
Argireline is the trade name for acetyl hexapeptide-3 (also designated acetyl hexapeptide-8 under INCI naming), a synthetic six-amino-acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) developed in the early 2000s as a topical cosmetic ingredient. It is marketed as a "Botox-like" anti-wrinkle agent and is one of the most widely used neuropeptide-mimetic ingredients in over-the-counter skincare. It is a cosmetic ingredient, not a drug, and is used topically rather than injected.
How it works
The peptide's sequence mimics the N-terminal domain of SNAP-25, a component of the SNARE protein complex that mediates fusion of acetylcholine-containing synaptic vesicles at the neuromuscular junction. By competing with native SNAP-25 for a position in the SNARE assembly, argireline is proposed to destabilize complex formation and partially inhibit calcium-dependent acetylcholine release, thereby reducing the muscle contractions that produce expression lines. This is mechanistically analogous in target (the SNARE/SNAP-25 pathway) to botulinum toxin, though botulinum toxin acts by proteolytically cleaving SNAP-25 intracellularly, a fundamentally different and far more potent action. The proposed mechanism is largely supported by in vitro and cell-based assays from the originating laboratory rather than by demonstration of neuromuscular blockade in intact human skin.
Mechanism pathways
Interfering with the vesicle-fusion machinery that releases acetylcholine at the neuromuscular junction.
Neurotransmitter release depends on a piece of molecular machinery called the SNARE complex. When a nerve impulse arrives and calcium enters the terminal, synaptobrevin on the vesicle membrane, together with syntaxin and SNAP-25 on the presynaptic membrane, zipper together into an extremely stable four-helix bundle. That zippering physically pulls the two membranes close enough to fuse, releasing the vesicle contents into the synaptic cleft. At the neuromuscular junction the transmitter is acetylcholine, and its release is what makes muscle contract. This machinery is the target of botulinum toxin, which is a protease: it enters the nerve terminal and enzymatically cleaves SNAP-25, permanently disabling those complexes and paralysing the muscle until new protein is made. Because repeated muscle contraction is what etches dynamic expression lines into skin over time, blocking it reduces those lines, which is the basis of a very large cosmetic industry. The peptides in this group were designed around the same target by a completely different route. Both mimic the amino-terminal segment of SNAP-25. The proposal is that they compete with native SNAP-25 for a position in the assembling SNARE complex, destabilising it and modestly reducing the efficiency of calcium-dependent vesicle fusion. This would lessen acetylcholine release without cleaving anything and without paralysis. One is a hexapeptide and the other a longer variant developed as a follow-on, and both are used as topical cosmetic ingredients. The mechanism is competitive and reversible rather than enzymatic and destructive, which makes it inherently far weaker. The central honest problem with this pathway is not the mechanism but the delivery, and it deserves to be stated plainly. These are hydrophilic, charged peptides of substantial molecular size. The stratum corneum is a lipid barrier specifically evolved to exclude exactly such molecules. For a topically applied peptide to work by this mechanism it would have to cross the stratum corneum, cross the full thickness of the epidermis and dermis, reach the neuromuscular junctions of facial muscles, and arrive at a concentration sufficient to compete with abundant native SNAP-25. The plausibility of that chain is the main scientific objection to the entire ingredient category. Reported cosmetic benefits may owe more to moisturisation and film-forming effects than to neuromuscular action, and controlled independent evidence is limited.
The evidence
The foundational paper (Blanes-Mira et al., Int J Cosmet Sci, 2002) reported the in vitro SNARE/exocytosis-inhibition data plus a small open-label in vivo study in which a topical emulsion reduced periocular wrinkle depth by roughly 30% over about a month, an uncontrolled, low-sample-size design from the developer. The most rigorous human data is a randomized, placebo-controlled study in 60 Chinese subjects (Wang et al., Am J Clin Dermatol, 2013) that reported statistically significant improvement in wrinkle measures versus placebo, though it was single-center and industry-relevant. A 2025 review (Zdrada-Nowak et al., Int J Mol Sci) concluded that available evidence suggests reductions in wrinkle depth and improvements in elasticity/hydration, but emphasized that many studies are small, short, vehicle-comparison or open-label, and that high-quality independent RCTs remain limited. A recurring, unresolved gap is that effects are modest and far weaker than injectable botulinum toxin, with no head-to-head trials establishing equivalence.
The evidence, in brief
A topical cosmetic peptide (acetyl hexapeptide-3/8) modelled on SNAP-25, claimed to soften expression lines by interfering with neurotransmitter release. Evidence is small, short-term cosmetic studies (e.g. reduced periorbital wrinkle roughness vs placebo over 4 weeks); effects are modest and below pharmaceutical standards.
- The anti-wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese subjectsJ Cosmet Laser Ther, 2013 (PMID 23607739)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #006
Some human signal atop preclinical work; gaps remain.
Some early human evidence exists but isn't definitive.
Claim receipts
Popular claims about Argireline, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
It interferes with the SNARE complex competitively rather than cleaving SNAP-25, and no head-to-head trial supports equivalence with an injectable neuromodulator.
One small randomized placebo-controlled study and several open-label or vehicle-comparison studies report modest improvement; independent high-quality trials remain limited.
Penetration work shows the peptide crosses the stratum corneum poorly, and neuromuscular blockade in intact human skin has never been demonstrated.
The tolerability record covers finished cosmetic formulations; powders for reconstitution and injectable preparations sit outside any cosmetic-ingredient safety review.
Safety profile
As a topical cosmetic peptide, argireline has a generally favorable tolerability profile in published studies, with reports of mild or no irritation and no documented systemic neuromuscular toxicity at cosmetic use levels. A central limitation is delivery: because the peptide is hydrophilic and relatively large, penetration through the stratum corneum is poor (Kraeling et al., 2015 showed limited in vitro skin penetration), which constrains how much reaches viable tissue and complicates interpretation of efficacy. Long-term safety data, data in diverse populations, and effects from non-topical or compounded routes are not well characterized; "research-grade" powders sold for reconstitution carry purity, sterility, and contamination uncertainties that fall outside the safety record of finished cosmetic formulations.
Compound notes
- Argireline (acetyl hexapeptide-8/3) is a topical cosmetic peptide often described as “Botox-like.”
- It is studied for modulating neurotransmitter release in skin to soften expression lines, topically, and far weaker than injectable botulinum toxin.
- A topical cosmetic ingredient, not a drug or injectable.
- Effects are modest and superficial compared with the comparison it invites.
Regulatory status
Argireline (acetyl hexapeptide-3/-8) is a cosmetic ingredient, not an FDA-approved drug; it is used in over-the-counter topical products and is not approved to treat any medical condition, and any "Botox alternative" claims are marketing rather than regulatory designations. It is not a controlled substance and is not specifically a WADA-prohibited compound; injectable, compounded, or "research-use-only" preparations are unapproved and outside any cosmetic-ingredient safety review.
Used topically as a cosmetic ingredient, not an approved drug.
By the numbers
- 01Acetyl hexapeptide-3 and acetyl hexapeptide-8 refer to the same six-amino-acid peptide; the names reflect different INCI conventions, not different molecules
- 02Sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 mimics the N-terminal end of SNAP-25, a SNARE-complex protein
- 03Developed and characterized by Lipotec; first described in a 2002 International Journal of Cosmetic Science paper
- 04Marketed as a topical 'Botox-like' peptide, but it works by competitive SNARE interference, not by cleaving SNAP-25 as botulinum toxin does
- 05Poor stratum-corneum penetration due to hydrophilicity and size is a major efficacy limitation noted across reviews
- 06Best controlled human evidence is a 60-subject randomized placebo-controlled study (2013); most other data is small or open-label
Argireline: research formats
Choose the format you are researching to see route-specific notes.
Cosmetic peptide only, applied to skin, not injected. No injectable research use.
Argireline (acetyl hexapeptide-8) is a cosmetic ingredient sold in liquid form for direct addition to serums and creams, or as part of finished cosmetic products. Typical concentrations in finished products are 5–10%. There is no established research or clinical injectable use for argireline.
Cosmetic vendors sell argireline as a concentrated solution (typically 10–25% in water) for DIY serum formulation. Standard usage is 5–10% of the total serum volume.
Sources
Every factual claim above resolves to a real, published source.
- A synthetic hexapeptide (Argireline) with antiwrinkle activityInternational Journal of Cosmetic Science, 2002, PMID 18498523
- The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled studyAmerican Journal of Clinical Dermatology, 2013, PMID 23417317
- In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulationCutaneous and Ocular Toxicology, 2015, PMID 24754410
- Acetyl Hexapeptide-8 in Cosmeceuticals: A Review of Skin Permeability and EfficacyInternational Journal of Molecular Sciences, 2025, PMID 40565185
Cite this page
PepCue. “Argireline: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/argireline.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.